Strategic Alliances
Synergy Partners has formed Strategic Alliances with selected organizations to extend our R&D capabilities and scope.
Strategic Partnerships allow clients to work strategically with Synergy to apply our deep drug discovery and development experience across a portfolio of programs in order to facilitate progression of an entire R&D pipeline for the client organization.
In addition, we collaborate with selected Partner Organizations to provide our clients with drug development services that expand the scope of our core expertise. These established, long-term partnerships are designed to facilitate seamless execution of your program as it transitions through development. Together, we will work with these trusted, highly skilled partners to continue to bring the right expertise at the right time to move your project forward.
Strategic Partnerships allow clients to work strategically with Synergy to apply our deep drug discovery and development experience across a portfolio of programs in order to facilitate progression of an entire R&D pipeline for the client organization.
In addition, we collaborate with selected Partner Organizations to provide our clients with drug development services that expand the scope of our core expertise. These established, long-term partnerships are designed to facilitate seamless execution of your program as it transitions through development. Together, we will work with these trusted, highly skilled partners to continue to bring the right expertise at the right time to move your project forward.
Strategic Partnerships
Synergy is supporting the Institute for Applied Cancer Science (IACS) at MD Anderson Cancer Center in the development of their internally discovered oncology pipeline.
Synergy has contributed strategic and operational expertise for the preclinical development of multiple IACS compounds from discovery through IND filing and continues to provide advice and support for projects in the IACS pipeline, from discovery through the early stages of clinical development.
Synergy has contributed strategic and operational expertise for the preclinical development of multiple IACS compounds from discovery through IND filing and continues to provide advice and support for projects in the IACS pipeline, from discovery through the early stages of clinical development.
Partner Organizations
ApconiX is a team of nonclinical toxicologists with extensive expertise in drug discovery and development and a commitment to advancing the science of drug safety. The ApconiX team includes experts in all major safety disciplines and also have an in house ion channel laboratory available.
Through the Strategic Alliance with Synergy, ApconiX scientists are available to bring additional strategic and operational expertise to your program, working with the Synergy team to support rapid and timely decisions on drug safety throughout the development spectrum. |
Brizzey, LLC is a team of industry professionals with deep experience in all aspects of clinical supply chain strategy and operations, and most particularly in support of First in Human studies. Brizzey is available to provide our clients with strategic and operational support as you begin to plan your early clinical supply chain. Timely access to this expertise is especially important during the late preclinical and early clinical stages of development, and the collaboration between Synergy Partners and Brizzey is designed to bring that expertise to your program in a way that is seamless and transparent.
Brizzey’s experience and established contacts with manufacturing, packaging and logistics service providers and their ability to facilitate effective interactions with these groups, as well as manage the challenges of global movement of all types of R&D materials will strengthen and support your program during these critical stages of development. |